trending Market Intelligence /marketintelligence/en/news-insights/trending/argcp2a-adfs06tezmtqmq2 content esgSubNav
In This List

Wright Medical's injectable bone graft approved for US market

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Wright Medical's injectable bone graft approved for US market

Wright Medical Group NV's injectable bone graft, named Augment, received premarket approval from the U.S. Food and Drug Administration for use in foot and ankle procedures.

With this decision, the injected formulation can be used for the same procedures as the noninjectable version.

Amsterdam, Netherlands-based Wright Medical will immediately begin finalizing FDA packaging procedures and expects to roll out the product within the next four to six weeks.

Wright projects a $300 million market opportunity in the U.S. for the injectable bone graft, adding in its press release that Augment is the first clinically proven injectable protein therapeutic to come to the U.S. market.